Rob Warren
Overview
Explore the profile of Rob Warren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Opperman C, Johannes C, Singh S, Ghebrekristos Y, Warren R, Esmail A, et al.
Diagn Microbiol Infect Dis
. 2024 Sep;
110(4):116531.
PMID: 39293319
The GenoType CMdirect Ver 1.0 and GenoType Mycobacterium Common Mycobacteria Ver 2.0-line probe assays were utilized to identify nontuberculous mycobacteria (NTM) from decontaminated sputum in a GeneXpert MTB/RIF Ultra negative...
2.
Opperman C, Harricombe W, Singh S, Ghebrekristos Y, Warren R
Indian J Tuberc
. 2024 Aug;
71(3):235-237.
PMID: 39111929
No abstract available.
3.
Van Rie A, Warren R
Lancet Infect Dis
. 2024 May;
24(10):1071-1072.
PMID: 38795711
No abstract available.
4.
Opperman C, Ntshangase Z, Gumede M, Singh S, Ghebrekristos Y, Warren R, et al.
S Afr J Infect Dis
. 2024 Apr;
39(1):576.
PMID: 38628427
No abstract available.
5.
Opperman C, Singh S, Goosen W, Cox H, Warren R, Esmail A
IJID Reg
. 2024 Feb;
10:140-145.
PMID: 38304760
Nontuberculous mycobacteria (NTM) are a group of acid-fast mycobacteria other than complex (MTBC) that cause pulmonary disease that is similar to the disease caused by MTBC. International guidelines for the...
6.
Opperman C, Wojno J, Goosen W, Warren R
Prog Mol Biol Transl Sci
. 2023 Sep;
201:41-92.
PMID: 37770176
Highly drug-resistant strains are not uncommon among the Mycobacterium genus, with patients requiring lengthy antibiotic treatment regimens with multiple drugs and harmful side effects. This alarming increase in antibiotic resistance...
7.
Van Rie A, De Vos E, Costa E, Verboven L, Ndebele F, Heupink T, et al.
Trials
. 2022 Oct;
23(1):864.
PMID: 36209235
Background: Rifampicin-resistant tuberculosis (RR-TB) remains an important global health problem. Ideally, the complete drug-resistance profile guides individualized treatment for all RR-TB patients, but this is only practised in high-income countries....
8.
Traore A, Rikhotso M, Banda N, Mashilo M, Ngandu J, Mavumengwana V, et al.
Pathogens
. 2022 Jun;
11(6).
PMID: 35745490
Background: In 2018, an estimated 10.0 million people contracted tuberculosis (TB), and 1.5 million died from it, including 1.25 million HIV-negative persons and 251,000 HIV-associated TB fatalities. Drug-resistant tuberculosis (DR-TB)...
9.
Pillay S, Steingart K, Davies G, Chaplin M, De Vos M, Schumacher S, et al.
Cochrane Database Syst Rev
. 2022 May;
5:CD014841.
PMID: 35583175
Background: The World Health Organization (WHO) End TB Strategy stresses universal access to drug susceptibility testing (DST). DST determines whether Mycobacterium tuberculosis bacteria are susceptible or resistant to drugs. Xpert...
10.
Oostvogels S, Ley S, Heupink T, Dippenaar A, Streicher E, De Vos E, et al.
Microb Genom
. 2022 Apr;
8(4).
PMID: 35471145
Extensively drug-resistant tuberculosis (XDR-TB), defined as resistance to at least isoniazid (INH), rifampicin (RIF), a fluoroquinolone (FQ) and a second-line injectable drug (SLID), is difficult to treat and poses a...